comparemela.com

Latest Breaking News On - Pharmaceuticals trading down - Page 2 : comparemela.com

Acumen Pharmaceuticals, Inc (NASDAQ:ABOS) Short Interest Down 12 0% in May

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 816,000 shares, a decrease of 12.0% from the April 30th total of 926,900 shares. Based on an average trading volume of 297,900 shares, […]

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) CFO Sells $114,972 06 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares in the company, […]

Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 1 1%

Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares dropped 1.1% during mid-day trading on Wednesday . The stock traded as low as C$2.78 and last traded at C$2.78. Approximately 6,065 shares changed hands during trading, a decline of 18% from the average daily volume of 7,410 shares. The stock had previously closed at C$2.81. […]

StockNews com Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Strong-Buy

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday. JAZZ has been the subject of a number of other reports. Stifel Nicolaus upped their price target on shares of Jazz Pharmaceuticals from $225.00 to […]

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Director Amy W Schulman Sells 21,700 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.